IDXG Insider Trading Activity and SEC Form 4 Filings
IDXG insider trading summary
No open-market insider purchases or sales of Interpace Biosciences, Inc. (IDXG) have been reported on SEC Form 4 in the past 12 months.
Latest IDXG insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 21, 2021 | Thomas W. Burnell | President & CEO | Buy | $94K (10,855 @ $8.68) |
| Mar 1, 2021 | Peter Kamin | 10% Owner | Buy | $45K (14,726 @ $3.08) |
| Mar 1, 2021 | Peter Kamin | 10% Owner | Buy | $25K (8,252 @ $3.08) |
| Mar 1, 2021 | Peter Kamin | 10% Owner | Buy | $9K (2,862 @ $3.08) |
| Mar 1, 2021 | Peter Kamin | 10% Owner | Buy | $50K (16,360 @ $3.08) |
| Feb 26, 2021 | Peter Kamin | 10% Owner | Buy | $47K (14,874 @ $3.17) |
| Feb 26, 2021 | Peter Kamin | 10% Owner | Buy | $26K (8,333 @ $3.17) |
| Feb 26, 2021 | Peter Kamin | 10% Owner | Buy | $47K (14,946 @ $3.17) |
| Feb 26, 2021 | Peter Kamin | 10% Owner | Buy | $9K (2,897 @ $3.17) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.